BioMarin Pharmaceutical Inc. (BMRN)

Over the past six months, several events have impacted BioMarin Pharmaceutical's stock price. BioMarin reported its Third Quarter 2025 financial results, raised its full-year 2025 total revenue guidance at the midpoint, and reaffirmed its Voxzogo full-year outlook. BioMarin announced its decision to pursue options to divest ROCTAVIAN. The FDA accepted BioMarin's supplemental Biologics License Application (sBLA) for PALYNZIQ® for Priority Review. BioMarin announced CEO changes and participated in the Jefferies Global Healthcare Conference. BioMarin presented compelling five-year Phase 3 results for ROCTAVIAN at the International Society on Thrombosis and Haemostasis (ISTH) 2025 Congress. BioMarin Pharmaceutical Inc. was dropped from the Russell 1000 Defensive Index. The company announced positive new data supporting the safety and efficacy of VOXZOGO®.

Specific data detailing the demand seasonality for BioMarin Pharmaceutical's products and services is not explicitly provided. However, recent financial reports indicate strong and growing demand for its therapies, with strong revenue growth in VOXZOGO® and PALYNZIQ® and anticipated sustained financial performance from its Enzyme Therapies and Skeletal Conditions business units, suggesting a consistent or increasing demand.

BioMarin Pharmaceutical, Inc. is a global biotechnology company focused on developing and commercializing therapies for serious and life-threatening rare genetic diseases, primarily affecting children, operating within the Medical sector, specifically in the Biotechnology and Pharmaceutical Preparations industries. The company's core business and research are in enzyme replacement therapies (ERTs), and it was a pioneer in providing therapeutics for mucopolysaccharidosis type I (MPS I) and phenylketonuria (PKU). Its portfolio includes Aldurazyme, Naglazyme, Kuvan, Firdapse, Vimizim, Brineura, Palynziq, Voxzogo, and Roctavian.

BioMarin Pharmaceutical Inc. is headquartered in San Rafael, California, U.S., and has a global presence with offices and facilities across the United States, South America, Asia, and Europe. Key regional offices and operations are located in Ireland, Brazil, and Japan, with a presence in Australia, Hong Kong, Taiwan, Dubai, Argentina, and Greece. The company operates manufacturing facilities in Novato, California, and Shanbally, Ireland.

BioMarin has faced criticism regarding its drug pricing and access to drugs in clinical trials, but its ongoing development and commercialization of therapies for rare genetic disorders contribute to its scientific reputation. Positive clinical trial results for ROCTAVIAN and positive data for VOXZOGO enhance its standing in the medical community.

BioMarin Pharmaceutical Inc. is predominantly owned by institutional shareholders, who hold approximately 92.42% of the stock, with insiders owning about 1.74% and retail investors holding 5.84%. Major institutional owners include BlackRock, Inc., Vanguard Group Inc., Primecap Management Co/Ca/, Dodge & Cox, State Street Corp, Viking Global Investors Lp, Aqr Capital Management Llc, Geode Capital Management, Llc, Millennium Management Llc, and Capital Research Global Investors.